

HIV | SURVEILLANCE DATA TABLES

**Core Indicators for Monitoring the
Ending the HIV Epidemic Initiative
(*preliminary data*):**

**National HIV Surveillance System Data
Reported Through September 2024**



U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE
CONTROL AND PREVENTION

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for persons with diagnosed HIV reported to CDC through September 2024.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through September 2024. *HIV Surveillance Data Tables* 2024;5(4). <https://www.cdc.gov/hiv-data/initiatives/>. Published December 2024. Accessed [date].

On the Web: <https://www.cdc.gov/hiv-data/initiatives/>

Confidential information, referrals, and educational material on HIV

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

This issue of *HIV Surveillance Data Tables* was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Taylor Jones, Zanetta Gant Sumner, Anna Satcher Johnson, Xiaohong Hu, Jianmin Li, Xueyuan Dong, Chan Jin, Emily Zhu, Stacy Cohen, and Michael Friend (editing and desktop publishing).

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Technical Notes	4
References	6
Tables	
1a HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2023 through September 2024—United States (preliminary)	7
1b HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2023 through September 2024—United States and 6 territories and freely associated states (preliminary)	8
1c HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2023 through September 2024—United States and 6 territories and freely associated states (preliminary)	9
1d HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2023 through September 2024—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	10
2a Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by selected characteristics, January 2023 through June 2024—48 states and the District of Columbia (preliminary)	12
2b Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2023 through June 2024—48 states and the District of Columbia (preliminary)	14
2c Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2023 through June 2024—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	16
3 Ending the HIV Epidemic Phase I jurisdictions	19

Technical Notes

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and by 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core indicators for monitoring the Ending the HIV Epidemic initiative* report, available at <https://stacks.cdc.gov/view/cdc/156512>.

The tables included in this report provide *preliminary* data on HIV diagnoses and linkage to HIV medical care for the years 2023 and 2024 based on cases reported to CDC as of September 2024. Data for the 2 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated. More information on HIV surveillance practices and limitations, demographic information, and geographic designations can be found in the Technical Notes of the *HIV Surveillance Report, 2022*, available at <https://stacks.cdc.gov/view/cdc/156509>.

TABULATION AND PRESENTATION OF DATA

HIV Diagnoses

HIV diagnoses are the numbers of persons aged ≥ 13 years with HIV diagnosed during January 2023 through September 2024 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2017–2021 diagnoses) found that, on average, approximately 80% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 98% of HIV diagnoses are reported to CDC by the end of the following year. Data for the years 2023 and 2024 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting HIV diagnoses can be found in the *HIV Surveillance Report, 2022*, available at <https://stacks.cdc.gov/view/cdc/156509>.

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years with HIV diagnosed during January 2023 through June 2024 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥ 13 years with HIV diagnosed during January 2023 through June 2024 and who had ≥ 1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years with HIV diagnosed during January 2023 through June 2024. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to the National HIV Surveillance System (NHSS); therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2023 through June 2024 and reported to NHSS through September 2024. Data for the years

2023 and 2024 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

Data are not provided for states and associated areas that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico. Data for Mississippi and West Virginia were included in analyses but should also be interpreted with caution due to a lapse in laboratory reporting that occurred during the year 2022.

More information on calculating linkage to care can be found in the report *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 territories and freely associated states, 2022*, available at <https://stacks.cdc.gov/view/cdc/156511>.

References

1. HHS. EHE Overview. <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated December 2023. Accessed November 19, 2024.

Table 1a. HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2023 through September 2024—United States (preliminary)

	No.	No.
	2023	2024 (January–September)
Gender		
Man	30,258	18,798
Woman	7,236	4,960
Transgender woman ^a	858	521
Transgender man ^a	79	55
Additional gender identity ^b	101	45
Age at diagnosis (yr)		
13–24	7,083	4,244
25–34	14,148	8,974
35–44	8,775	5,678
45–54	4,723	3,021
55–64	2,864	1,794
≥65	946	681
Race/ethnicity		
American Indian/Alaska Native	199	119
Asian	807	496
Black/African American	14,720	10,052
Hispanic/Latino ^c	12,868	7,803
Native Hawaiian/other Pacific Islander	56	63
White	8,897	5,373
Multiracial	992	486
Transmission category^d		
Male-to-male sexual contact ^e	25,534	15,984
Injection drug use ^f		
Male	1,393	817
Female	1,079	661
Male-to-male sexual contact ^e and injection drug use ^f	1,348	715
Heterosexual contact ^g		
Male	2,908	1,834
Female	6,198	4,331
Other ^h		
Male	35	21
Female	45	29
Region of residenceⁱ		
Northeast	5,194	3,399
Midwest	5,232	3,403
South	20,205	13,299
West	7,908	4,291
Total^j	38,539	24,392

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through September 2024. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman.

“Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

^b Additional gender identity examples include “nonbinary,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of reported data by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

^e Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^g Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

ⁱ Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

^j Includes persons of unknown gender.

Table 1b. HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2023 through September 2024—United States and 6 territories and freely associated states (preliminary)

	No. 2023	No. 2024 (January–September)
Gender		
Man	30,590	18,972
Woman	7,298	4,995
Transgender woman ^a	862	524
Transgender man ^a	79	56
Additional gender identity ^b	101	45
Age at diagnosis (yr)		
13–24	7,133	4,272
25–34	14,298	9,048
35–44	8,854	5,722
45–54	4,777	3,051
55–64	2,910	1,814
≥65	965	698
Race/ethnicity		
American Indian/Alaska Native	200	119
Asian	808	496
Black/African American	14,726	10,057
Hispanic/Latino ^c	13,247	8,006
Native Hawaiian/other Pacific Islander	57	67
White	8,906	5,374
Multiracial	993	486
Transmission category^d		
Male-to-male sexual contact ^e	25,789	16,117
Injection drug use ^f		
Male	1,408	825
Female	1,080	663
Male-to-male sexual contact ^e and injection drug use ^f	1,349	720
Heterosexual contact ^g		
Male	2,974	1,865
Female	6,258	4,363
Other ^h		
Male	35	21
Female	45	31
Region of residenceⁱ		
Northeast	5,194	3,399
Midwest	5,232	3,403
South	20,205	13,299
West	7,908	4,291
U.S. territories and freely associated states	398	213
Total^j	38,937	24,605

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. U.S. territories and freely associated states include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the U.S. Virgin Islands, and the Republic of Palau. Data are for cases reported to CDC through September 2024. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman. “Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

^b Additional gender identity examples include “nonbinary,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of reported data by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

^e Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^g Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

ⁱ Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

^j Includes persons of unknown gender.

Table 1c. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2023 through September 2024—United States and 6 territories and freely associated states (preliminary)

Area of residence	No.	No.
	2023	2024 (January–September)
Alabama	706	371
Alaska	26	24
Arizona	933	497
Arkansas	296	263
California	4,750	2,326
Colorado	477	300
Connecticut	244	155
Delaware	101	78
District of Columbia	189	59
Florida	4,478	3,422
Georgia	2,384	1,622
Hawaii	56	46
Idaho	47	15
Illinois	1,417	767
Indiana	672	464
Iowa	137	83
Kansas	148	94
Kentucky	396	241
Louisiana	862	662
Maine	36	47
Maryland	719	505
Massachusetts	534	259
Michigan	697	503
Minnesota	323	217
Mississippi	519	300
Missouri	556	341
Montana	27	15
Nebraska	98	71
Nevada	559	340
New Hampshire	35	25
New Jersey	962	552
New Mexico	173	73
New York	2,372	1,635
North Carolina	1,399	1,001
North Dakota	21	9
Ohio	857	655
Oklahoma	372	173
Oregon	242	141
Pennsylvania	937	648
Rhode Island	64	68
South Carolina	865	536
South Dakota	52	20
Tennessee	900	627
Texas	5,053	2,778
Utah	173	154
Vermont	10	10
Virginia	868	597
Washington	424	350
West Virginia	98	64
Wisconsin	254	179
Wyoming	21	10
Subtotal	38,539	24,392
U.S. territories and freely associated states		
American Samoa	0	1
Guam	4	3
Northern Mariana Islands	0	0
Puerto Rico	381	199
Republic of Palau	0	0
U.S. Virgin Islands	13	10
Subtotal	398	213
Total	38,937	24,605

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of HIV diagnosis. Numbers less than 12 should be interpreted with caution. Data are for cases reported to CDC through September 2024. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 1d. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2023 through September 2024—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	No.	No.
	2023	2024 (January–September)
Arizona		
Maricopa County	617	305
California		
Alameda County	189	103
Los Angeles County	1,593	811
Orange County	263	150
Riverside County	295	161
Sacramento County	162	24
San Bernardino County	284	136
San Diego County	377	183
San Francisco County	185	132
District of Columbia	189	59
Florida		
Broward County	557	436
Duval County	252	189
Hillsborough County	358	226
Miami-Dade County	1,026	812
Orange County	474	330
Palm Beach County	271	251
Pinellas County	153	126
Georgia		
Cobb County	164	94
DeKalb County	308	213
Fulton County	441	340
Gwinnett County	239	155
Illinois		
Cook County	960	502
Indiana		
Marion County	260	217
Louisiana		
East Baton Rouge Parish	130	99
Orleans Parish	129	114
Maryland		
Baltimore City	169	111
Montgomery County	98	70
Prince George's County	194	156
Massachusetts		
Suffolk County	145	61
Michigan		
Wayne County	293	218
Nevada		
Clark County	500	303
New Jersey		
Essex County	193	117
Hudson County	121	72

Table 1d. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2023 through September 2024—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	No.	No.
	2023 (cont)	2024 (January–September) (cont)
New York		
Bronx County	412	274
Kings County	473	360
New York County	299	219
Queens County	435	251
North Carolina		
Mecklenburg County	272	203
Ohio		
Cuyahoga County	146	119
Franklin County	209	120
Hamilton County	105	75
Pennsylvania		
Philadelphia County	332	180
Puerto Rico		
San Juan Municipio	88	54
Tennessee		
Shelby County	353	226
Texas		
Bexar County	380	198
Dallas County	831	550
Harris County	1,313	761
Tarrant County	334	209
Travis County	209	149
Washington		
King County	174	165
Total	17,954	11,389

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of HIV diagnosis. Data are for cases reported to CDC through September 2024. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2023 through June 2024—48 states and the District of Columbia (preliminary)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2023				
Gender					
Man	29,449	24,470	83.1	4,979	16.9
Woman	7,057	5,765	81.7	1,292	18.3
Transgender woman ^a	840	718	85.5	122	14.5
Transgender man ^a	78	69	88.5	9	11.5
Additional gender identity ^b	99	89	89.9	10	10.1
Age at diagnosis (yr)					
13–24	6,918	5,667	81.9	1,251	18.1
25–34	13,779	11,473	83.3	2,306	16.7
35–44	8,542	7,054	82.6	1,488	17.4
45–54	4,585	3,831	83.6	754	16.4
55–64	2,789	2,326	83.4	463	16.6
≥65	917	765	83.4	152	16.6
Race/ethnicity					
American Indian/Alaska Native	198	167	84.3	31	15.7
Asian	789	682	86.4	107	13.6
Black/African American	14,384	11,536	80.2	2,848	19.8
Hispanic/Latino ^c	12,389	10,570	85.3	1,819	14.7
Native Hawaiian/other Pacific Islander	56	50	89.3	6	10.7
White	8,758	7,314	83.5	1,444	16.5
Multiracial	956	797	83.4	159	16.6
Transmission category^d					
Male-to-male sexual contact ^e	24,913	20,885	83.8	4,029	16.2
Injection drug use ^f	2,397	1,883	78.5	514	21.5
Male	1,335	1,035	77.5	300	22.5
Female	1,062	848	79.8	214	20.2
Male-to-male sexual contact ^e and injection drug use ^f	1,325	1,061	80.1	264	19.9
Heterosexual contact ^g	8,817	7,222	81.9	1,595	18.1
Male	2,781	2,269	81.6	513	18.4
Female	6,035	4,953	82.1	1,082	17.9
Total^h	37,530	31,116	82.9	6,414	17.1

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2023 through June 2024—48 states and the District of Columbia (preliminary) (cont)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2024 (January–June)				
Gender					
Man	14,144	11,832	83.7	2,312	16.3
Woman	3,717	3,076	82.8	641	17.2
Transgender woman ^a	408	341	83.6	67	16.4
Transgender man ^a	41	38	92.7	3	7.3
Additional gender identity ^b	36	34	94.4	2	5.6
Age at diagnosis (yr)					
13–24	3,234	2,631	81.4	603	18.6
25–34	6,844	5,748	84.0	1,096	16.0
35–44	4,227	3,549	84.0	678	16.0
45–54	2,211	1,851	83.7	360	16.3
55–64	1,334	1,116	83.7	218	16.3
≥65	504	433	85.9	71	14.1
Race/ethnicity					
American Indian/Alaska Native	93	82	88.2	11	11.8
Asian	378	323	85.4	55	14.6
Black/African American	7,503	6,040	80.5	1,463	19.5
Hispanic/Latino ^c	5,952	5,170	86.9	782	13.1
Native Hawaiian/other Pacific Islander	44	33	75.0	11	25.0
White	3,998	3,345	83.7	653	16.3
Multiracial	386	335	86.8	51	13.2
Transmission category^d					
Male-to-male sexual contact ^e	12,064	10,129	84.0	1,935	16.0
Injection drug use ^f	1,116	908	81.4	208	18.6
Male	608	497	81.7	111	18.3
Female	508	411	81.0	97	19.0
Male-to-male sexual contact ^e and injection drug use ^f	542	461	85.1	81	14.9
Heterosexual contact ^g	4,593	3,797	82.7	796	17.3
Male	1,361	1,110	81.5	252	18.5
Female	3,232	2,688	83.2	544	16.8
Total^h	18,354	15,328	83.5	3,026	16.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are for cases reported to CDC through September 2024, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are based on residence at time of HIV diagnosis. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

^a “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman. “Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

^b Additional gender identity examples include “nonbinary,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of reported data by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

^e Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^g Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^h Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful. Total also includes persons of unknown gender.

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2023 through June 2024—48 states and the District of Columbia (*preliminary*)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2023				
Alabama	706	580	82.2	126	17.8
Alaska	26	22	84.6	4	15.4
Arizona	933	777	83.3	156	16.7
Arkansas	296	253	85.5	43	14.5
California	4,750	4,025	84.7	725	15.3
Colorado	477	399	83.6	78	16.4
Connecticut	244	210	86.1	34	13.9
Delaware	101	83	82.2	18	17.8
District of Columbia	189	158	83.6	31	16.4
Florida	4,478	3,691	82.4	787	17.6
Georgia	2,384	1,953	81.9	431	18.1
Hawaii	56	46	82.1	10	17.9
Illinois	1,417	1,200	84.7	217	15.3
Indiana	672	521	77.5	151	22.5
Iowa	137	127	92.7	10	7.3
Kansas	148	119	80.4	29	19.6
Kentucky	396	325	82.1	71	17.9
Louisiana	862	713	82.7	149	17.3
Maine	36	35	97.2	1	2.8
Maryland	719	636	88.5	83	11.5
Massachusetts	534	479	89.7	55	10.3
Michigan	697	563	80.8	134	19.2
Minnesota	323	292	90.4	31	9.6
Mississippi ^a	519	401	77.3	118	22.7
Missouri	556	464	83.5	92	16.5
Montana	27	25	92.6	2	7.4
Nebraska	98	85	86.7	13	13.3
Nevada	559	470	84.1	89	15.9
New Hampshire	35	27	77.1	8	22.9
New Mexico	173	142	82.1	31	17.9
New York	2,372	2,041	86.0	331	14.0
North Carolina	1,399	1,110	79.3	289	20.7
North Dakota	21	18	85.7	3	14.3
Ohio	857	712	83.1	145	16.9
Oklahoma	372	309	83.1	63	16.9
Oregon	242	222	91.7	20	8.3
Pennsylvania	937	798	85.2	139	14.8
Rhode Island	64	58	90.6	6	9.4
South Carolina	865	757	87.5	108	12.5
South Dakota	52	45	86.5	7	13.5
Tennessee	900	639	71.0	261	29.0
Texas	5,053	4,042	80.0	1,011	20.0
Utah	173	134	77.5	39	22.5
Vermont	10	9	90.0	1	10.0
Virginia	868	721	83.1	147	16.9
Washington	424	365	86.1	59	13.9
West Virginia ^a	98	66	67.3	32	32.7
Wisconsin	254	229	90.2	25	9.8
Wyoming	21	20	95.2	1	4.8

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2023 through June 2024—48 states and the District of Columbia (preliminary) (cont)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2024 (January–June)				
Alabama	264	124	47.0	140	53.0
Alaska	19	18	94.7	1	5.3
Arizona	462	389	84.2	73	15.8
Arkansas	177	148	83.6	29	16.4
California	1,876	1,614	86.0	262	14.0
Colorado	226	176	77.9	50	22.1
Connecticut	128	112	87.5	16	12.5
Delaware	55	47	85.5	8	14.5
District of Columbia	56	46	82.1	10	17.9
Florida	2,435	2,013	82.7	422	17.3
Georgia	1,214	1,023	84.3	191	15.7
Hawaii	31	26	83.9	5	16.1
Illinois	641	567	88.5	74	11.5
Indiana	343	285	83.1	58	16.9
Iowa	55	49	89.1	6	10.9
Kansas	66	56	84.8	10	15.2
Kentucky	185	144	77.8	41	22.2
Louisiana	455	378	83.1	77	16.9
Maine	39	32	82.1	7	17.9
Maryland	393	344	87.5	49	12.5
Massachusetts	234	215	91.9	19	8.1
Michigan	367	310	84.5	57	15.5
Minnesota	158	141	89.2	17	10.8
Mississippi ^a	235	160	68.1	75	31.9
Missouri	262	216	82.4	46	17.6
Montana	14	13	92.9	1	7.1
Nebraska	53	48	90.6	5	9.4
Nevada	298	267	89.6	31	10.4
New Hampshire	17	10	58.8	7	41.2
New Mexico	56	45	80.4	11	19.6
New York	1,286	1,139	88.6	147	11.4
North Carolina	726	578	79.6	148	20.4
North Dakota	8	8	100.0	0	0.0
Ohio	483	424	87.8	59	12.2
Oklahoma	134	108	80.6	26	19.4
Oregon	97	82	84.5	15	15.5
Pennsylvania	484	421	87.0	63	13.0
Rhode Island	49	46	93.9	3	6.1
South Carolina	400	304	76.0	96	24.0
South Dakota	14	13	92.9	1	7.1
Tennessee	437	328	75.1	109	24.9
Texas	2,441	2,036	83.4	405	16.6
Utah	119	80	67.2	39	32.8
Vermont	7	7	100.0	0	0.0
Virginia	438	370	84.5	68	15.5
Washington	236	210	89.0	26	11.0
West Virginia ^a	49	40	81.6	9	18.4
Wisconsin	125	112	89.6	13	10.4
Wyoming	7	6	85.7	1	14.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are for cases reported to CDC through September 2024, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are based on residence at time of HIV diagnosis. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

^a Data should be interpreted with caution due to a lapse in laboratory data completeness that occurred during the year 2022.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2023 through June 2024—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2023				
Arizona					
Maricopa County	617	521	84.4	96	15.6
California					
Alameda County	189	165	87.3	24	12.7
Los Angeles County	1,593	1,338	84.0	255	16.0
Orange County	263	237	90.1	26	9.9
Riverside County	295	241	81.7	54	18.3
Sacramento County	162	143	88.3	19	11.7
San Bernardino County	284	209	73.6	75	26.4
San Diego County	377	328	87.0	49	13.0
San Francisco County	185	176	95.1	9	4.9
District of Columbia	189	158	83.6	31	16.4
Florida					
Broward County	557	443	79.5	114	20.5
Duval County	252	195	77.4	57	22.6
Hillsborough County	358	298	83.2	60	16.8
Miami-Dade County	1,026	843	82.2	183	17.8
Orange County	474	396	83.5	78	16.5
Palm Beach County	271	223	82.3	48	17.7
Pinellas County	153	119	77.8	34	22.2
Georgia					
Cobb County	164	138	84.1	26	15.9
DeKalb County	308	258	83.8	50	16.2
Fulton County	441	361	81.9	80	18.1
Gwinnett County	239	204	85.4	35	14.6
Illinois					
Cook County	960	820	85.4	140	14.6
Indiana					
Marion County	260	219	84.2	41	15.8
Louisiana					
East Baton Rouge Parish	130	105	80.8	25	19.2
Orleans Parish	129	107	82.9	22	17.1
Maryland					
Baltimore City	169	155	91.7	14	8.3
Montgomery County	98	87	88.8	11	11.2
Prince George's County	194	173	89.2	21	10.8
Massachusetts					
Suffolk County	145	132	91.0	13	9.0
Michigan					
Wayne County	293	227	77.5	66	22.5
Nevada					
Clark County	500	421	84.2	79	15.8
New York					
Bronx County	412	345	83.7	67	16.3
Kings County	473	382	80.8	91	19.2
New York County	299	248	82.9	51	17.1
Queens County	435	391	89.9	44	10.1

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2023 through June 2024—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2023 (cont)				
North Carolina					
Mecklenburg County	272	230	84.6	42	15.4
Ohio					
Cuyahoga County	146	124	84.9	22	15.1
Franklin County	209	183	87.6	26	12.4
Hamilton County	105	89	84.8	16	15.2
Pennsylvania					
Philadelphia County	332	287	86.4	45	13.6
Tennessee					
Shelby County	353	230	65.2	123	34.8
Texas					
Bexar County	380	305	80.3	75	19.7
Dallas County	831	660	79.4	171	20.6
Harris County	1,313	1,048	79.8	265	20.2
Tarrant County	334	269	80.5	65	19.5
Travis County	209	190	90.9	19	9.1
Washington					
King County	174	151	86.8	23	13.2
Total	17,552	14,572	83.0	2,980	17.0
	2024 (January–June)				
Arizona					
Maricopa County	296	257	86.8	39	13.2
California					
Alameda County	85	75	88.2	10	11.8
Los Angeles County	656	551	84.0	105	16.0
Orange County	109	101	92.7	8	7.3
Riverside County	133	107	80.5	26	19.5
Sacramento County	22	20	90.9	2	9.1
San Bernardino County	124	93	75.0	31	25.0
San Diego County	164	152	92.7	12	7.3
San Francisco County	98	95	96.9	3	3.1
District of Columbia	56	46	82.1	10	17.9
Florida					
Broward County	326	269	82.5	57	17.5
Duval County	129	101	78.3	28	21.7
Hillsborough County	154	132	85.7	22	14.3
Miami-Dade County	566	460	81.3	106	18.7
Orange County	235	195	83.0	40	17.0
Palm Beach County	183	156	85.2	27	14.8
Pinellas County	90	70	77.8	20	22.2
Georgia					
Cobb County	75	63	84.0	12	16.0
DeKalb County	152	129	84.9	23	15.1
Fulton County	250	209	83.6	41	16.4
Gwinnett County	118	102	86.4	16	13.6
Illinois					
Cook County	431	384	89.1	47	10.9

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2023 through June 2024—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2024 (January–June) (<i>cont</i>)				
Indiana					
Marion County	156	134	85.9	22	14.1
Louisiana					
East Baton Rouge Parish	66	55	83.3	11	16.7
Orleans Parish	79	66	83.5	13	16.5
Maryland					
Baltimore City	85	78	91.8	7	8.2
Montgomery County	53	45	84.9	8	15.1
Prince George's County	118	104	88.1	14	11.9
Massachusetts					
Suffolk County	57	55	96.5	2	3.5
Michigan					
Wayne County	160	134	83.8	26	16.3
Nevada					
Clark County	269	241	89.6	28	10.4
New York					
Bronx County	210	185	88.1	25	11.9
Kings County	284	246	86.6	38	13.4
New York County	179	158	88.3	21	11.7
Queens County	198	175	88.4	23	11.6
North Carolina					
Mecklenburg County	158	133	84.2	25	15.8
Ohio					
Cuyahoga County	82	76	92.7	6	7.3
Franklin County	89	77	86.5	12	13.5
Hamilton County	52	48	92.3	4	7.7
Pennsylvania					
Philadelphia County	124	101	81.5	23	18.5
Tennessee					
Shelby County	151	91	60.3	60	39.7
Texas					
Bexar County	177	144	81.4	33	18.6
Dallas County	471	385	81.7	86	18.3
Harris County	674	561	83.2	113	16.8
Tarrant County	188	159	84.6	29	15.4
Travis County	115	104	90.4	11	9.6
Washington					
King County	95	86	90.5	9	9.5
Total	8,742	7,408	84.7	1,334	15.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are based on residence at time of HIV diagnosis. Data are for cases reported to CDC through September 2024, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

Table 3. Ending the HIV Epidemic Phase I jurisdictions

Counties	Territories	States
Arizona	Puerto Rico^a	Alabama
Maricopa County	San Juan Municipio ^a	Arkansas
California		Kentucky
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
District of Columbia		
Florida		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
Georgia		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
Illinois		
Cook County		
Indiana		
Marion County		
Louisiana		
East Baton Rouge Parish		
Orleans Parish		
Maryland		
Baltimore City		
Montgomery County		
Prince George's County		
Massachusetts		
Suffolk County		
Michigan		
Wayne County		
Nevada		
Clark County		
New Jersey^a		
Essex County ^a		
Hudson County ^a		
New York		
Bronx County		
Kings County		
New York County		
Queens County		

Table 3. Ending the HIV Epidemic Phase I jurisdictions (cont)

Counties	Territories	States
North Carolina		
Mecklenburg County		
Ohio		
Cuyahoga County		
Franklin County		
Hamilton County		
Pennsylvania^a		
Philadelphia County		
Tennessee		
Shelby County		
Texas		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
Washington		
King County		

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.

^a Linkage to care data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: New Jersey and Puerto Rico.